BioGaia AB’s Nomination Committee for the 2027 Annual General Meeting

BioGaia AB’s Nomination Committee for the Annual General Meeting 2027 has been appointed based on the ownership structure as of June 30, 2026.

The Nomination Committee for the Annual General Meeting 2027 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Alexander Kahane (Chairman of the Nomination Committee), appointed by the largest shareholder Anatom Holding AG, Anders Oscarsson, appointed by Corvatsch Invest AG, Karsten Ferm, appointed by Fjärde AP-Fonden, and Caroline Sjösten, appointed by Swedbank Robur. In addition, Mauricio Graber is a member of the Nomination Committee in his capacity as Chairman of the Board.

Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by letter to the address:

BioGaia AB, Nomination Committee,
Kungsbroplan 3A, 112 27 Stockholm.
 

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Mauricio Graber, Chairman of the Board
Email: [email protected]
Phone: +46 (0)8 555 293 00

Caroline Mofors, Chief Legal Officer
Email: [email protected]
Phone: +46 (0)8 555 293 00

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com